Beneficial effects of treatment with cystamine on brain in NZB/W F1 mice

European Journal of Pharmacology

Volumn 591, Issue 1-3, 2008, Pages 307-314

  Hsu, Tsai Ching ^a   Chen, Yi Chen ^a   Lai, Wen Xian ^a   Chiang, Szu Yi ^b   Huang, Chih Yang ^c,d   Tzang, Bor Show ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b Hualien Hospital   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; MMP 9 (Matrix metalloproteinase 9); NF B; NP SLE (Neuropsychiatric SLE); uPA (Urokinase type plasminogen activator)

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 9; CYSTAMINE; GELATINASE A; GELATINASE B; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; PROTEIN BAD; PROTEIN BCL 2; TRANSCRIPTION FACTOR RELA; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; BRAIN; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; MOUSE; NEUROPSYCHIATRY; NEW ZEALAND BLACK MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; APOPTOSIS; BRAIN; CYSTAMINE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED NZB; MITOCHONDRIA; TRANSCRIPTION FACTOR RELA; URINARY PLASMINOGEN ACTIVATOR;

EID: 48749094949     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.06.078     Document Type: Article

References (42)

1. Ainiala H., Hietaharju A., Dastidar P., Loukkola J., Lehtimäki T., Peltola J., Korpela M., Heinonen T., and Nikkari S.T. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum. 50 (2004) 858-865
2. Asherson R.A., Denburg S.D., Denburg J.A., Carbotte R.M., and Futrell N. Current concepts of neuropsychiatric systemic lupus erythematosus (NP-SLE). Postgrad. Med. J. 69 (1993) 602-608
3. Bonfa E., and Elkon K.B. Clinical and serologic associations of the antiribosomal P protein antibody. Arthritis Rheum. 29 (1986) 981-985
4. Bonfa E., Golombek S.J., Kaufman L.D., Skelly S., Weissbach H., Brot N., and Elkon K.B. Association between lupus psychosis and anti-ribosomal P protein antibodies. N. Engl. J. Med. 317 (1987) 265-271
5. Boumpas D.T., Yamada H., Patronas N.J., Scott D., Klippel J.H., and Balow J.E. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q. J. Med. 81 (1991) 975-984
6. Brown I.R. Heat shock proteins and protection of the nervous system. Ann. NY. Acad. Sci. 1113 (2007) 147-158
7. Burggraf D., Trinkl A., Dichgans M., and Hamann G.F. Doxycycline inhibits MMPs via modulation of plasminogen activators in focal cerebral ischemia. Neurobiol. Dis. 25 (2007) 506-513
8. Currie R.W., Ellison J.A., White R.F., Feuerstein G.Z., Wang X., and Barone F.C. Benign focal ischemic preconditioning induces neuronal Hsp70 and prolonged astrogliosis with expression of Hsp27. Brain Res. 863 (2000) 169-181
9. Faber-Elmann A., Sthoeger Z., Tcherniack A., Dayan M., and Mozes E. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin. Exp. Immunol. 127 (2002) 393-398
10. Feinglass E.J., Arnett F.C., Dorsch C.A., Zizic T.M., and Stevens M.B. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore) 55 (1976) 323-339
11. Folk J.E. Transglutaminases. Annu. Rev. Biochem. 49 (1980) 517-531
12. Fox J.H., Barber D.S., Singh B., Zucker B., Swindell M.K., Norflus F., Buzescu R., Chopra R., Ferrante R.J., Kazantsev A., and Hersch S.M. Cystamine increases l-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J. Neurochem. 91 (2004) 413-442
13. Franklin T.B., Krueger-Naug A.M., Clarke D.B., Arrigo A.P., and Currie R.W. The role of heat shock proteins Hsp70 and Hsp27 in cellular protection of the central nervous system. Int. J. Hyperth. 21 (2005) 379-392
14. Futrell N., Schultz L.R., and Millikan C. Central nervous system disease in patients with systemic lupus erythematosus. Neurology 42 (1992) 1649-1657
15. Goetzl E.J., Banda M.J., and Leppert D. Matrix metalloproteinases and immunity. J. Immunol. 156 (1996) 1-4
16. Hanly J.G., and Liang M.H. Cognitive disorders in systemic lupus erythematosus. Epidemiologic and clinical issues. Ann. NY. Acad. Sci. 823 (1997) 60-68
17. Hsu T.C., Chiang S.Y., Huang C.Y., Tsay G.J., Yang C.W., Huang C.N., and Tzang B.S. Beneficial effects of treatment with transglutaminase inhibitor cystamine on macrophage response in NZB/W F1 mice. Exp. Biol. Med. 232 (2007) 195-203
18. Hsu T.C., Huang C.Y., Chiang S.Y., Lai W.X., Tsai C.H., and Tzang B.S. Transglutaminase inhibitor cystamine alleviates the abnormality in liver from NZB/W F1 mice. Eur. J. Pharmacol. 579 (2008) 382-389
19. Ientile R., Campisi A., Raciti G., Caccamo D., Currò M., Cannavò G., Li Volti G., Macaione S., and Vanella A. Cystamine inhibits transglutaminase and caspase-3 cleavage in glutamate-exposed astroglial cells. J. Neurosci. Res. 74 (2003) 52-59
20. Jonsson H., Nived O., and Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 68 (1989) 141-150
21. Kaell A.T., Shetty M., Lee B.C., and Lockshin M.D. The diversity of neurologic events in systemic lupus erythematosus. Prospective clinical and computed tomographic classification of 82 events in 71 patients. Arch. Neurol. 43 (1986) 273-276
22. Karpuj M.V., Becher M.W., Springer J.E., Chabas D., Youssef S., Pedotti R., Mitchell D., and Steinman L. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8 (2002) 143-149
23. Koscec M., Koren E., Wolfson-Reichlin M., Fugate R.D., Trieu E., Targoff I.N., and Reichlin M. Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture. J. Immunol. 159 (1997) 2033-2041
24. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
25. Lesort M., Lee M., Tucholski J., and Johnson G.V. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. 278 (2003) 3825-3830
26. Lorand L., and Conrad S.M. Transglutaminases. Mol. Cell. Biochem. 58 (1984) 9-35
27. McCune W.J., and Golbus J. Neuropsychiatric lupus. Rheum. Dis. Clin. North. Am. 14 (1988) 149-167
28. Menshikov M., Elizarova E., Plakida K., Timofeeva A., Khaspekov G., Beabealashvilli R., Bobik A., and Tkachuk V. Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis. Biochem. J. 367 (2002) 833-839
29. Nagai T., Arinuma Y., Yanagida T., Yamamoto K., and Hirohata S. Anti-ribosomal P protein antibody in human systemic lupus erythematosus up-regulates the expression of proinflammatory cytokines by human peripheral blood monocytes. Arthritis Rheum. 52 (2005) 847-855
30. Nakayama H., Ikebe T., Beppu M., and Shirasuna K. High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 92 (2001) 3037-3044
31. Ramos-DeSimone N., Hahn-Dantona E., Sipley J., Nagase H., French D.L., and Quigley J.P. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 274 (1999) 13066-13076
32. Schram B.R., and Rothstein T.L. NF-kappa B is required for surface Ig-induced Fas resistance in B cells. J. Immunol. 170 (2003) 3118-3124
33. Shishodia S., Sethi G., Konopleva M., Andreeff M., and Aggarwal B.B. A synthetic triterpenoid, CDDO-Me, inhibits IkappaB alpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappa B-regulated gene products in human leukemic cells. Clin. Cancer Res. 12 (2006) 1828-1838
34. Sibley J.T., Olszynski W.P., Decoteau W.E., and Sundaram M.B. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J. Rheumatol. 19 (1992) 47-52
35. Stafford H.A., Chen A.E., Anderson C.J., Paul A.G., Wyatt E.L., Lee L.A., and Neas B.R. Anti-ribosomal and 'P-peptide'-specific autoantibodies bind to T lymphocytes. Clin. Exp. Immunol. 109 (1997) 12-19
36. Toubi E., and Shoenfeld Y. Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun. Rev. 6 (2007) 119-125
37. Trysberg E., Blennow K., Zachrisson O., and Tarkowski A. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res. Ther. 6 (2004) R551-R556
38. Tzang B.S., Chiang S.Y., Lai W.X., Tsai C.C., Wu J.H., and Hsu T.C. Treatment with cystamine reduces apoptosis in liver from NZB/W F1 mice. Int. Immunopharmacol. 8 (2008) 589-596
39. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., and Baldwin A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281 (1998) 1680-1683
40. Yenari M.A., Liu J., Zheng Z., Vexler Z.S., Lee J.E., and Giffard R.G. Antiapoptotic and anti-inflammatory mechanisms of heat-shock protein protection. Ann. NY. Acad. Sci. 1053 (2005) 74-83
41. Zhang H.G., Huang N., Liu D., Bilbao L., Zhang X., Yang P., Zhou T., Curiel D.T., and Mountz J.D. Gene therapy that inhibits nuclear translocation of nuclear factor kappaB results in tumor necrosis factor alpha-induced apoptosis of human synovial fibroblasts. Arthritis Rheum. 43 (2000) 1094-1105
42. Zheng Z., Kim J.Y., Ma H., Lee J.E., and Yenari M.A. Anti-inflammatory effects of the 70 kDa heat shock protein in experimental stroke. J. Cereb. Blood Flow Metab. 28 (2008) 53-63